The Phase I/II trial investigated the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine, demonstrating tumor responses in patients with ovarian cancer [7]. This evidence concerns the gene CHEK1 and ovarian cancer.